{
    "nct_id": "NCT02992483",
    "official_title": "Phase I Open Label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacokinetics of Intravenously Administered MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",
    "inclusion_criteria": "Inclusion Criteria\n\n* Age â‰¥ 18 years.\n* Histologically confirmed lymphoma (WHO classification), or confirmed MM (IMWG), that is relapsed and/or refractory.\n* Other Inclusion Criteria May Apply.\n\nExclusion Criteria\n\n* Known history of chronic liver disease\n* History of chronic pancreatitis.\n* Prior treatment with Mcl-1 inhibitor.\n* Other Exclusion Criteria May Apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}